ChemicalBook > CAS DataBase List > Cinpanemab
Cinpanemab
- Product Name
- Cinpanemab
- CAS No.
- 2094516-02-4
- Chemical Name
- Cinpanemab
- Synonyms
- BIIB054;Cinpanemab;Research Grade Cinpanemab;Cinpanemab (anti-Alpha-synuclein);Research Grade Cinpanemab(DHE22001)
- CBNumber
- CB88081153
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Cinpanemab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Cinpanemab Chemical Properties,Usage,Production
Uses
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease[1][2].
in vivo
Cinpanemab (30 mg/kg; i.p.) improves PD-like phenotypes in α-syn PFF inoculation mouse models [2].
| Animal Model: | C57BL/6JRccHsd WT mice, transgenic M83 mice expressing human α-syn A53T, and transgenic bacterial artificial chromosome mice expressing human α-syn A53T were anesthetized and stereotaxically injected with α-syn preformed fibrils (PFFs) into the right forebrain[2] |
| Dosage: | 30 mg/kg |
| Administration: | Intraperitoneal (i.p.) injections 2-3 times prior to α-syn PFF injection and weekly post-injection until time of sacrifice |
| Result: | Attenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum. |
IC 50
α-synuclein
References
[1] Lang AE, et, al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):408-420. DOI:10.1056/NEJMoa2203395
[2] Teng JS, et, al. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20(9):802-813. DOI:10.2174/1871527320666210526160926
Cinpanemab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Cinpanemab Suppliers
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 57505
- Advantage
- 58
2094516-02-4, CinpanemabRelated Search:
Cobolimab
bimekizumab
Vedolizumab
Polatuzumab vedotin
Cofetuzumab
Cusatuzumab
Tinurilimab
Dacliximab
Otelixizumab
Gatralimab